Article Text

Download PDFPDF

Short report
Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity
  1. Maarten R Hillen1,2,
  2. Katia Urso3,
  3. Emma Koppe3,
  4. Ana Pinheiro Lopes1,2,
  5. Sofie L M Blokland1,2,
  6. Aridaman Pandit1,2,
  7. Tom Slocombe3,
  8. André van Maurik4,
  9. Joel A G van Roon1,2 and
  10. Timothy R D J Radstake1,3
  1. 1Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
  2. 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
  3. 3GSK Immunology Network and Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK
  4. 4Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Stevenage, UK
  1. Correspondence to Dr Joel AG van Roon; j.vanroon{at}umcutrecht.nl

Statistics from Altmetric.com

Tripartite motif-containing protein 21 (TRIM21)/Ro52 is an immunoglobulin receptor that together with Ro60 makes up Sjögren’s syndrome-antigen A (SSA). A 60%–80% of patients with primary Sjögren’s syndrome (pSS) have anti-SSA autoantibodies and they form part of the pSS diagnosis. TRIM21 is a cytosolic Fc-receptor that mediates neutralisation of opsonised viruses and other particles, acting as a last line of defence against viruses that are recognised by antibodies but still manage to penetrate the cell membrane.1 In addition, TRIM21 regulates type I interferon (IFN) responses by mediating either stabilisation or degradation of IFN regulatory factors.1 2 Uniquely, it has a very broad antibody specificity and recognises IgA, IgG and IgM antibodies with high affinity, allowing TRIM21 to be effective against a large range of viruses.3 Alternatively, TRIM21 can be triggered by immune complexes containing non-viral particles such as cellular debris or nucleic acids,4 leading to rapid production of pro-inflammatory mediators including type I IFNs.2 Interestingly, mice immunised with TRIM21 develop anti-TRIM21 autoantibodies and salivary gland inflammation, while transfer of serum from anti-TRIM21-positive mice to naïve mice induces salivary gland dysfunction,5 suggesting a direct link between anti-TRIM21 autoantibodies and induction of Sjögren’s-like symptoms.

Considering the relevance of TRIM21 as autoantigen in pSS and its role in regulating IFN signalling, we here investigated its expression in the major type I IFN-producing immune cells, plasmacytoid dendritic cells (pDCs) and monocytes, from patients with pSS. In addition, we investigated TRIM21 expression in salivary gland tissue. For pDCs and salivary gland tissues, RNA sequencing and analysis were performed separately as previously described.6 7 For monocytes, TRIM21 expression was assessed using quantitative PCR (online supplementary methods) We observed increased mRNA expression of TRIM21 in purified pDCs from patients with pSS compared to both healthy controls and patients with non-Sjögren’s sicca …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.